Updated prognostic models and the current state of treatment for myelodysplastic syndrome and myeloproliferative neoplasms (MDS/MPN) were outlined in a recent review of myeloid neoplasms with overlapping MDS/MPN features.
The authors note that next-generation sequencing studies have led to a better understanding of MDS/MPN disease biology, and that combining the molecular findings to patho-morphologic features has improved the precision of MDS/MPN diagnosis and prognostic models. They address updates in MDS/MPN nomenclature and diagnostic criteria based on the revised 2016 WHO classification of myeloid neoplasms, and point to the need for continued data integration that leads to comprehensive genomic characterization, improved prognostic tools, and novel therapies.
Thota S, Gerds A. Myelodysplastic and myeloproliferative neoplasms: Updates on the overlap syndromes. [Published online ahead of print August 3, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1357179.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al